Asset
ZALIFRELIMAB
Revenue
No revenue reported in loaded filings.
Clinical trials (5)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05033132 | phase2 | withdrawn | 2021-10-01 | 2024-12-30 | Agenus Inc. | A Phase II Study of Balstilimab Independently or in Combination With Zalifrelimab in Advanced Cervical Cancer |
| NCT03495882 | phase1_2 | completed | 2017-12-18 | 2022-07-15 | Agenus Inc. | A Study of Zalifrelimab and Balstilimab for Treatment of Participants With Metastatic or Locally Advanced Solid Tumors, and Expansion Into Select Solid Tumors (Cervical) |
| NCT02694822 | phase1_2 | completed | 2016-04-01 | 2022-03-30 | Agenus Inc. | AGEN1884, an Anti-CTLA-4 Human Monoclonal Antibody in Participants With Advanced or Refractory Cancer and Who Have Progressed With PD-1/PD-L1 Inhibitor as Their Most Recent Therapy |
| NCT04607200 | phase2 | withdrawn | 2021-02-01 | 2021-09-13 | Agenus Inc. | AGEN2034 & AGEN1884 in Patients With Recurrent, Inoperable Angiosarcoma |
| NCT03894215 | phase2 | terminated | 2019-06-01 | 2025-03-26 | Agenus Inc. | RaPiDS- A Phase 2 Study of Anti-PD-1 Independently or in Combination With Anti-CTLA-4 in Second-Line Cervical Cancer |
FDA applications (0)
This company has no applications containing this asset.